Lurbinectedin in Refractory Diffuse Malignant Peritoneal Mesothelioma: Report of Two Cases
Autor: | Solange Peters, Niklaus Schaefer, Louis Gros, Antonella Diciolla, Martin Hübner, Petr Szturz, Antonia Digklia, Volker Kirchner |
---|---|
Jazyk: | angličtina |
Rok vydání: | 2021 |
Předmět: |
0301 basic medicine
Cancer Research medicine.medical_specialty Lurbinectedin lurbinectedin Disease Malignancy 03 medical and health sciences 0302 clinical medicine Peritoneum Refractory durable response peritoneal mesothelioma case report palliative chemotherapy peritoneal tumor medicine Mesothelioma RC254-282 business.industry Neoplasms. Tumors. Oncology. Including cancer and carcinogens respiratory system medicine.disease 030104 developmental biology medicine.anatomical_structure Oncology 030220 oncology & carcinogenesis Perspective Peritoneal mesothelioma Hyperthermic intraperitoneal chemotherapy Radiology business |
Zdroj: | Frontiers in Oncology, Vol 11 (2021) Frontiers in Oncology Frontiers in oncology, vol. 11, pp. 704295 |
Popis: | Mesothelioma is a malignancy of serosal membranes. Parietal pleura is the most common site, with peritoneum being the second most frequent location. Malignant peritoneal mesothelioma (MPM) is a rare and aggressive disease. The prognosis is often very poor with median overall survival ranging from 6 to 18 months in patients who are not candidates for cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) due to non-resectable disease or comorbid conditions. For patients with resectable disease, CRS and HIPEC have become the standard of care. However, for patients with unresectable malignant mesothelioma there is unfortunately no effective systemic treatment beyond the first line. Based on the results of a recent phase II trial, lurbinectedin has clinical activity and acceptable toxicity in the second- and third-line treatment of malignant pleural mesothelioma. However, until present, no data have been available for patients with MPM and for patients who become refractory after multiple treatment lines. We report on two patients with metastatic MPM who achieved durable disease control of 10+ and 8 months with lurbinectedin in the fourth and fifth treatment line, respectively. |
Databáze: | OpenAIRE |
Externí odkaz: |